Since the first report of IFN-α as an effective treatment for CDA-I in 1995, [3] its use has been limited by the need for thrice-weekly or twice-weekly injections, which affects long-term adherence. This evidence concerns the gene IFNA1 and congenital dyserythropoietic anemia type 1.